Budesonide DR is a Small Molecule owned by Calliditas Therapeutics, and is involved in 15 clinical trials, of which 10 were completed, 3 are ongoing, and 2 are planned.
Budesonide (Nefecon, PL-56) is glucocorticoid receptor agonist. The drug candidate down regulates the inflammatory process in the kidneys through suppression of the gut immune system. Glucocorticoids suppress inflammation mainly by switching off multiple activated inflammatory genes through reversing histone acetylation through the recruitment of histone deacetylase-2 (HDAC2).
The revenue for Budesonide DR is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Budesonide DR NPV Report.
Budesonide DR Overview
Budesonide (Tarpeyo, Kinpeygo) is a glucocorticoid that acts as an anti inflammatory agent. It is formulated as delayed release capsules and modified release hard capsules for oral route of administration. Tarpeyo is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.
Calliditas Therapeutics Overview
Calliditas Therapeutics, formerly Pharmalink develops, identifies, and commercializes pharmaceutical products for niche indications. The company’s pipeline products include Busulipo that is under Phase II clinical trials and Nefecon for IgA Nephritis that is under Phase II clinical trials. Its pipeline product also comprises Xepol XP-28 that is used for the treatment of post-polio syndrome and is under pre-license sales. Calliditas Therapeutics also partners with medical research institutions such as the Karolinska Institute and Uppsala University. The company offers its products and services across Sweden. Calliditas Therapeutics is headquartered in Stockholm, Sweden.
The company reported revenues of (Swedish Krona) SEK229.4 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of SEK0.9 million in FY2020. The operating loss of the company was SEK524.5 million in FY2021, compared to an operating loss of SEK379.7 million in FY2020. The net loss of the company was SEK500.3 million in FY2021, compared to a net loss of SEK433.5 million in FY2020. The company reported revenues of SEK260.1 million for the third quarter ended September 2022, compared to a revenue of SEK64.1 million the previous quarter.
Quick View – Budesonide DR
|Highest Development Stage|